Nelde, A., Kowalewski, D. J., Backert, L., Schuster, H., Werner, J., Klein, R., . . . Walz, J. S. (2018). HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Oncoimmunology.
शिकागो स्टाइल उद्धरणNelde, Annika, et al. "HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under Lenalidomide Treatment Confirms the Suitability of Lenalidomide for Combination With T-cell-based Immunotherapy." Oncoimmunology 2018.
एमएलए उद्धरणNelde, Annika, et al. "HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under Lenalidomide Treatment Confirms the Suitability of Lenalidomide for Combination With T-cell-based Immunotherapy." Oncoimmunology 2018.